FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898522021> ?p ?o ?g. }

• W2898522021 endingPage "502" @default.
• W2898522021 startingPage "491" @default.
• W2898522021 abstract "La anemia es frecuente en los pacientes en hemodiálisis, y su tratamiento con estimulantes de la eritropoyesis (AEE) resulta complejo debido a múltiples factores. Valorar la utilidad del modelo de control de anemia (MCA) en el tratamiento de la anemia en hemodiálisis. El MCA es un software que predice la dosis óptima de darbepoetina y hierro sacarosa para alcanzar niveles de hemoglobina (Hb) y ferritina deseados, emitiendo sugerencias de prescripción. Estudio realizado en clínicas de diálisis de 18 meses de duración en dos fases de intervención (FI) con MCA (FI1, n: 213; FI2, n: 218) separadas por una fase de control (FC, n: 219). El resultado primario fue el porcentaje de Hb en rango y la mediana de dosis de AEE y los resultados secundarios fueron las transfusiones, las hospitalizaciones o los acontecimientos cardiovasculares. Análisis a nivel de clínica y de pacientes valorando la variabilidad de la Hb mediante la desviación estándar (DE) de esta. También se analizaron pacientes con la mayoría de sugerencias confirmadas (grupo MCA cumplidores) El MCA aumentó el porcentaje de Hb en rango: 80,9% FI2 frente a 72,7% en FC, y redujo el consumo de darbepoetina (FI1: 20 [70]; FC 30 [80] μg, p = 0,032) con menor fluctuación de la Hb (0,91 ± 0,49 en FC a 0,82 ± 0,37 g/dl en FI2; p < 0,05) mejorando en el grupo MCA cumplidores. En cuanto a los resultados secundarios, descendieron con el uso del MCA. El MCA ayuda a obtener mejores resultados de anemia en los pacientes en hemodiálisis, minimizando los riesgos del tratamiento con AEE y reduciendo costes. Anaemia is common in haemodialysis patients and treating it with erythropoiesis-stimulating agents (ESAs) is complex due to many factors. To assess the usefulness of the Anaemia Control Model (ACM) in the treatment of anaemia in haemodialysis. ACM is a software that predicts the optimal dose of darbepoetin and iron sucrose to achieve target haemoglobin (Hb) and ferritin levels, and makes prescription suggestions. Study conducted in dialysis clinics lasting 18 months with two intervention phases (IPs) with ACM (IP1, n: 213; IP2, n: 218) separated by a control phase (CP, n: 219). The primary outcome was the percentage of Hb in range and the median dose of ESAs, and the secondary outcomes were transfusion, hospitalisation and cardiovascular events. Clinical and patient analyses were performed. Hb variability was assessed by the standard deviation (SD) of the Hb. We also analysed the patients with most of the suggestions confirmed (ACM compliant group). ACM increased the percentage of Hb in range: 80.9% in IP2, compared with 72.7% in the CP and reduced the intake of darbepoetin (IP1: 20 [70]; CP 30 [80] μg P = 0.032) with less Hb fluctuation (0.91 ± 0.49 in the CP to 0.82 ± 0.37 g/dl in IP2, P < 0.05), improving in the ACM compliant group. The secondary outcomes decreased with the use of ACM. ACM helps to obtain better anaemia results in haemodialysis patients, minimising the risks of treatment with ESAs and reducing costs." @default.
• W2898522021 created "2018-11-02" @default.
• W2898522021 creator A5005235998 @default.
• W2898522021 creator A5007646908 @default.
• W2898522021 creator A5021217170 @default.
• W2898522021 creator A5038201881 @default.
• W2898522021 creator A5040697405 @default.
• W2898522021 creator A5049200921 @default.
• W2898522021 creator A5051196057 @default.
• W2898522021 creator A5059862752 @default.
• W2898522021 creator A5085700534 @default.
• W2898522021 creator A5085770859 @default.
• W2898522021 date "2018-09-01" @default.
• W2898522021 modified "2023-09-25" @default.
• W2898522021 title "El modelo de control de anemia: ¿ayuda al nefrólogo en la decisión terapéutica para el manejo de la anemia?" @default.
• W2898522021 cites W1963824520 @default.
• W2898522021 cites W1967874232 @default.
• W2898522021 cites W1970297185 @default.
• W2898522021 cites W1982791970 @default.
• W2898522021 cites W1982950315 @default.
• W2898522021 cites W1998943227 @default.
• W2898522021 cites W2008447184 @default.
• W2898522021 cites W2029738096 @default.
• W2898522021 cites W2036372943 @default.
• W2898522021 cites W2036435483 @default.
• W2898522021 cites W2040029744 @default.
• W2898522021 cites W2041972553 @default.
• W2898522021 cites W2072976749 @default.
• W2898522021 cites W2087565789 @default.
• W2898522021 cites W2090564671 @default.
• W2898522021 cites W2092922936 @default.
• W2898522021 cites W2099142274 @default.
• W2898522021 cites W2104861758 @default.
• W2898522021 cites W2105642896 @default.
• W2898522021 cites W2106114378 @default.
• W2898522021 cites W2107643987 @default.
• W2898522021 cites W2109223284 @default.
• W2898522021 cites W2111074329 @default.
• W2898522021 cites W2113969374 @default.
• W2898522021 cites W2117118570 @default.
• W2898522021 cites W2121664270 @default.
• W2898522021 cites W2126606511 @default.
• W2898522021 cites W2128490296 @default.
• W2898522021 cites W2129349191 @default.
• W2898522021 cites W2132204418 @default.
• W2898522021 cites W2134487085 @default.
• W2898522021 cites W2141487347 @default.
• W2898522021 cites W2150953623 @default.
• W2898522021 cites W2151511116 @default.
• W2898522021 cites W2152157740 @default.
• W2898522021 cites W2154362351 @default.
• W2898522021 cites W2165551972 @default.
• W2898522021 cites W2293616896 @default.
• W2898522021 cites W2387948389 @default.
• W2898522021 cites W2419121537 @default.
• W2898522021 cites W2584947097 @default.
• W2898522021 cites W4243225397 @default.
• W2898522021 cites W3149132779 @default.
• W2898522021 doi "https://doi.org/10.1016/j.nefro.2018.03.004" @default.
• W2898522021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29875061" @default.
• W2898522021 hasPublicationYear "2018" @default.
• W2898522021 type Work @default.
• W2898522021 sameAs 2898522021 @default.
• W2898522021 citedByCount "8" @default.
• W2898522021 countsByYear W28985220212020 @default.
• W2898522021 countsByYear W28985220212021 @default.
• W2898522021 countsByYear W28985220212022 @default.
• W2898522021 crossrefType "journal-article" @default.
• W2898522021 hasAuthorship W2898522021A5005235998 @default.
• W2898522021 hasAuthorship W2898522021A5007646908 @default.
• W2898522021 hasAuthorship W2898522021A5021217170 @default.
• W2898522021 hasAuthorship W2898522021A5038201881 @default.
• W2898522021 hasAuthorship W2898522021A5040697405 @default.
• W2898522021 hasAuthorship W2898522021A5049200921 @default.
• W2898522021 hasAuthorship W2898522021A5051196057 @default.
• W2898522021 hasAuthorship W2898522021A5059862752 @default.
• W2898522021 hasAuthorship W2898522021A5085700534 @default.
• W2898522021 hasAuthorship W2898522021A5085770859 @default.
• W2898522021 hasBestOaLocation W28985220211 @default.
• W2898522021 hasConcept C126322002 @default.
• W2898522021 hasConcept C2778248108 @default.
• W2898522021 hasConcept C29456083 @default.
• W2898522021 hasConcept C71924100 @default.
• W2898522021 hasConceptScore W2898522021C126322002 @default.
• W2898522021 hasConceptScore W2898522021C2778248108 @default.
• W2898522021 hasConceptScore W2898522021C29456083 @default.
• W2898522021 hasConceptScore W2898522021C71924100 @default.
• W2898522021 hasIssue "5" @default.
• W2898522021 hasLocation W28985220211 @default.
• W2898522021 hasOpenAccess W2898522021 @default.
• W2898522021 hasPrimaryLocation W28985220211 @default.
• W2898522021 hasRelatedWork W1506200166 @default.
• W2898522021 hasRelatedWork W1995515455 @default.
• W2898522021 hasRelatedWork W2048182022 @default.
• W2898522021 hasRelatedWork W2080531066 @default.
• W2898522021 hasRelatedWork W2604872355 @default.
• W2898522021 hasRelatedWork W2748952813 @default.
• W2898522021 hasRelatedWork W2899084033 @default.

• next